Probiodrug AG
New treatment for Alzheimer's, prevention of toxic pE-Abeta, QC-Inhibitor to enter Phase II, disease-modifying, dominant IP, no therapy yet
- Stage Product In Development
- Industry Biotechnology
- Location Halle, SA, Deutschland
- Currency USD
- Founded July 1997
- Employees 20
- Website probiodrug.de
Company Summary
Probiodrug discovers and develops novel drugs for neuronal diseases. Its patent portfolio provides a dominant position for glutaminyl cyclase (QC) inhibition with the lead PQ912 ready to enter Phase II. QC, a novel target, is essential for the formation of pyroglutamated (pE) Abeta, which plays a crucial role in the pathogenesis of Alzheimer’s disease (AD). Likewise, the company is pursuing a pE-specific antibody as immunotherapy for AD.
Team
Advisors
-
SNP MunichLawyerUnconfirmedKPMGAccountantUnconfirmed
Previous Investors
-
BB Biotech, IBG, Ed. de Rothschild Investment Partners, IBG,UnconfirmedTVM Capital, HBM BioVentures, Life Sciences PartnersUnconfirmedCFH Group - LBBW Group, Biogen Idec, Wellington ManagementUnconfirmed
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.